rate for NSCLC patients has not improved over the past three decades. Therefore, understanding the mechanism of drug resistance is crucial for better treatment of cancer patients.
Many factors contribute to the development of drug resistance in cancer. The genetic and epigenetic abnormity of cancer cells is the most commonly-studied mechanism underlying drug resistance. 3 Interestingly, recent studies have shown that not only the tumor cells themselves but also the tumor microenvironment (TME) may provide a protective niche for cancer cells from chemotherapy and lead to drug resistance. [4] [5] [6] The TME consists of extracellular matrix (ECM), certain types of cells such as fibroblasts, neuroendocrine cells, adipose cells, immune-inflammatory cells, as well as the blood and lymphatic vascular networks. 7 CAF are among the major stromal cells in the TME.
Although the origin of CAF is still under debate, accumulating ev- Cancer-associated fibroblasts can provide pro-survival signaling to the adjacent tumor cells by producing growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β) and stromal cell-derived factor-1 (SDF-1), in a paracrine manner. 9, 10 However, the role of CAF in lung cancer chemoresistance has not been elucidated. In the present study, we have explored the effect of CAF on cisplatin resistance of lung cancers. We found that CAF decrease the chemosensitivity of lung cancer cells through inhibiting cisplatin-induced apoptosis by activating the ANXA3/JNK pathway.
| MATERIAL SANDME THODS

| Reagentsandantibodies
Cisplatin (CDDP) was purchased from Sigma-Aldrich (St Louis, MO, USA). JNK inhibitor SP600125 was purchased from Sigma-Aldrich and dissolved in DMSO. Antibodies used for western blotting were rab- neutralizing antibody was purchased from Sigma-Aldrich.
| Cellculture
Human lung cancer cell lines A549, H661 and SK-MES-1 were purchased from American Type Culture Collection (Manassas, VA, USA).
Cells were grown and maintained in DMEM medium (GIBCO BRL, Grand Island, NY, USA) at 37°C, 5% CO 2 . Medium was supplemented with 10% FBS.
| Isolationandcultureofstromalfibroblasts
Cancer-associated fibroblasts were isolated from primary tumor tissue as previously described. 11 CAF were cultured in DMEM/F12 medium supplemented with 10% FBS at 37°C, 5% CO 2 . For the preparation of CAF-conditioned medium (CAF-CM), CAF were cultured for 48 hours; the CAF-CM was collected and centrifuged for 10 minutes at 1500 g to remove cell debris. All in vitro experiments were performed in triplicate and CAF were at <10 passages.
The lung cancer tissues were obtained from patients at Tianjin
Medical University General Hospital (TMUGH, Tianjin, China), who underwent surgery without chemotherapy treatment history. Informed consent was obtained from all patients for the collection and use of specimens, and the study was approved by the Institutional Review Board of TMUGH.
| Cellviabilityassay
Cell viability was assessed by using the Cell Counting Kit-8 (CCK- 
| Flowcytometricevaluationofapoptosis
Lung cancer cells were treated with CDDP for 24 hours. After the treatment, the apoptotic cells were determined using an Annexin V- 
| RNAinterferenceandtransfection
The siRNA duplexes were purchased from Genepharma (Shanghai, China). The sequences of siRNA duplex for ANXA3 were: sense:
5′-GG-ACAAGCAGGCAAAUGAATT-3′, anti-sense: 5′-UUCAUUU 
| Westernblotting
Western blotting was performed as previously described. 13 Briefly, protein was extracted from cells using a RIPA lysis buffer containing protease inhibitor (Sigma-Aldrich). The proteins were separated by running a 12% SDS-PAGE and transferred to a nitrocellulose membrane (Millipore, Bedford, MA, USA). The membranes were blocked with 5%
non-fat milk for 1.5 hours at room temperature. Then the membranes were probed with primary antibodies at 4°C overnight and further incubated with the HRP-conjugated secondary antibodies at 37°C for 1.5 hours. Finally, the protein bands were visualized using the ECL Western Blotting System following the manufacturer's instructions.
| RNAsequencing
Total RNA was extracted from CAF and NF using the RNeasy Kit (Qiagen), following the manufacturer's instructions. The RNA sequencing was conducted on a BGISEQ -500 by BGI (Shenzhen, China). 6 weeks, mice were killed, and tumor tissues were dissected and used for mRNA and protein extraction.
| Invivotumorstudies
| Statisticalanalysis
The data were presented as mean ± SD. The statistical analysis was performed using SPSS21.0 (SPSS, Chicago, IL, USA). Variance analysis between multiple groups was performed by one-way ANOVA.
Differences between 2 groups were evaluated by Student's t-test.
Statistical significance was defined as P < 0.05.
| RE SULTS
| Cancer-associatedfibroblastsenhanced cisplatinresistanceoflungcancercells
For broader interest, we chose 3 lung cancer cell lines, A549 cells 
| Cancer-associatedfibroblastselevatedthe expressionlevelofANXA3inlungcancercells
Cancer-associated fibroblasts and NF possess different characters and play different roles, based on their gene expression profiles.
We compared the mRNA expression profiles between CAF and NF by applying the RNA-Sequence (RNA-Seq) approach. Our RNA-Seq data showed that 219 genes were upregulated in CAF compared to NF, whereas, 158 genes were downregulated in CAF compared to NF ( Figure 2A ). The gene ontology analysis classified these modulated genes into 3 categories: biological process, cellular component and molecular function ( Figure 2B ). In the biological process Figure 2F showed that CAF-CM incubation dramatically increased the ANXA3 level in all 3 lung cancer cell lines at both mRNA and protein levels.
Although CAF-CM incubation increased the ANXA3 level in lung cancer cells, we need to further demonstrate whether the increased ANXA3 level in cancer cells is due to ANXA3 secretion in CAF. We manipulated ANXA3 levels in CAF by overexpression or RNAi knock down. We found that when ANXA3 was overexpressed in CAF, its levels in lung cancer cells were increased accordingly ( Figure 3A) ; whereas when ANXA3 level was reduced by RNAi knockdown, its levels in lung cancer cells were also decreased ( Figure 3B ). Furthermore, we manipulated ANXA3 levels in medium. The ANXA3 recombinant protein was added to the culture medium to mimic the ANXA3 containing CAF-CM. Figure 3C shows that ANXA3 recombinant protein enhanced ANXA3 levels in cancer cells. We further added the ANXA3 neutralizing antibody to CAF-CM, and we found that the blockage of ANXA3 secretion in CAF attenuated ANXA3 upregulation ( Figure 3C ). These results demonstrated that ANXA3 level increase in cancer cells via ANXA3 secretion in CAF.
| ANXA3mediatedtheeffectof cancer-associatedfibroblastsoncisplatin resistanceoflungcancercells
To investigate the role of ANXA3 in the enhancement of CAF on chemoresistance, the expression of ANXA3 in lung cancer cells was manipulated. Because A549 and H661 cells expressed lower levels 
| Cancer-associatedfibroblastsactivatedJNK/ survivinpathwaybyupregulatingANXA3
Numerous studies have shown that mitogen activated-protein kinase (MAPK) signaling pathway plays an important role in cell proliferation, cell survival and drug resistance. JNK is a member of the MAPK family and is closely related to tumor development. This prompted us to explore the effect of CAF on JNK pathway.
Lung cancer cells were treated with cisplatin, with and without CAF-CM pre-treatment. Compared with cisplatin-only treatment, CAF-CM significantly increased the expression of both ANXA3 and p-JNK. In contrast, CAF-CM decreased the expression of apoptosisrelated genes cleaved caspase 8 and caspase 3, also survivin, which was activated by cisplatin ( Figure 6A ). We further overexpressed ANXA3 in A549 and H661 cells, then treated cells with cisplatin.
We found that ANXA3 elevated the p-JNK level, and reduced the cleaved caspase-8, caspase-3 and survivin level, which had a similar effect as CAF. However, when ANXA3 expression was reduced by
RNAi in SK-MES-1 cells, the JNK activation was suppressed, and the effect of cisplatin on caspases activation was reversed ( Figure 6B ). 
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| Cancer-associatedfibroblastsenhanced cisplatinresistanceoflungcancercellsinvivo
To explore the effect of CAF on chemoresistance in vivo, we conducted animal experiments to evaluate the effect of CAF on tumor growth and drug resistance. A549 cells alone or combined with CAF were subcutaneously injected into mice and treated with cisplatin. For direct comparison, A549 cells alone group and A549 combined with CAF group were injected into the same mouse; A549 cells alone treated with cisplatin group and A549
plus CAF treated with cisplatin were injected into the same mouse.
Cancer-associated fibroblasts boosted tumor growth significantly in mice; the average tumor volume of A549 cells combined with the CAF group was 2.5-fold larger than for the A549 alone group after 6 weeks. As expected, cisplatin inhibited A549 cell growth in mice; interestingly, CAF dramatically enhanced tumor growth under cisplatin treatment ( Figure 8A,B) . These results indicated that CAF enhanced tumor growth and chemoresistance.
Next, we investigated the ANXA3 status and JNK/survivin pathway in tumors. The tumor tissues were dissected, and the ANXA3
and JNK pathway were examined by immunoblotting. Consistent with in vitro study, ANXA3 expression was increased, the level of p-JNK and survivin was also elevated. On the other hand, apoptosisrelated genes caspase 3 and 8 was suppressed ( Figure 8C ). These results demonstrated that CAF enhance A549 xenograft growth and cisplatin resistance, through the JNK/survivin pathway activation via ANXA3. Numerous studies have shown that CAF promote drug resistance in several types of tumor, such as breast cancer, 14 ovarian cancer, 15 pancreatic cancer 16 and colorectal cancer. 17 To investigate the effect of CAF on cisplatin resistance of lung cancer, we collected the CAF-CM and cultured lung cancer cells in CAF-CM. We found that CAF-CM dramatically affects the cisplatin sensitivity of lung cancer cells.
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Cancer-associated fibroblasts can secrete CAF-specific proteins, cytokines, growth factors and ECM components to support tumor cell growth, angiogenesis and confer chemoresistance. 18 To identify whether the CAF-secreted proteins contribute to drug resistance, we first performed RNA-Seq on CAF compared to NF. Among upregulated genes in CAF, ANXA3 drew our attention. ANXA3, a member of the annexin family, binds to acidic phospholipids in a calcium-dependent manner. 19 Recent studies show that ANXA3
plays an important role in tumor growth and progression. Clinical evidence indicates that ANXA3 could be a potential biomarker of several types of cancers, such as bladder cancer, 20 colon cancer 21 and gastric cancer. 22 It can also serve as an important marker for the invasion, the metastasis and the prognosis of breast cancer.
23
ANXA3 is highly expressed in gastric cancer tissue and cell lines, and overexpression of ANXA3 promoted cell proliferation and colony formation. 22 Zhou et al 24 reported that inhibition of ANXA3
suppressed the proliferation and invasion of breast cancer cells.
Interestingly, ANXA3 also involved in chemoresistance. Sorafenibresistant hepatocellular carcinoma cells and patient-derived xenografts expressed a high level of ANXA3. Overexpression of ANXA3
in sorafenib-resistant hepatocellular carcinoma cells suppressed apoptosis, whereas anti-ANXA3 monoclonal antibody potentiated the effect of sorafenib. 25 The study by Pan et al. 26 also showed that ANXA3 promoted the resistance of hepatocellular carcinoma cells The main mechanisms of cisplatin resistance include decreased drug absorption and increased drug efflux, mutations of drug targeted genes, enhanced DNA repair capacity, increased cell proliferation and activation of anti-apoptotic signaling pathways. 27 Because the ultimate goal of cisplatin and most chemotherapeutic drugs is to induce apoptosis of tumor cells, the evasion of apoptosis becomes a key feature of acquired cisplatin resistance in tumor cells. 28 Survivin is a member of the family of inhibitor of apoptosis (IAP), which is involved in the inhibition of apoptosis. To further explore the mechanism underlying the promoting effect of CAF on cisplatin resistance of lung cancer cell, we explored the signaling pathways involved in cell proliferation and survival.
MAPK is an important intracellular signaling system which is responsible for transmitting various extracellular signals into the cells. It regulates a variety of physiological processes, including metabolism, survival, cell division and apoptosis. 33, 34 JNK is a member of the MAPK family; it plays a controversial roles in drug resistance.
Platinum continuously activates JNK to reduce drug-induced apoptosis, and inhibition of JNK activation increases the drug sensitivity of small cell lung cancer. 35 Rincon et al 36 In summary, our study showed that CAF significantly enhanced cisplatin resistance in lung cancer cells. We further demonstrated that CAF potentiated chemoresistance by suppressing cisplatin induced apoptosis by activating the ANXA3/JNK signaling pathway ( Figure 9 ). Targeting tge ANXA3/JNK signaling pathway could be a novel strategy to overcome lung cancer resistance to cisplatin and merits further clinical evaluation.
D I SCLOS U R E
There are no conflicts of interest to disclose.
O RCI D
Ke Xu https://orcid.org/0000-0001-8158-3399
